We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
+15%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$298M
AUM Growth
+$36.1M
(+14%)
Cap. Flow
-$1.63M
Cap. Flow
% of AUM
-0.55%
Top 10 Holdings %
Top 10 Hldgs %
50.06%
Holding
56
New
4
Increased
19
Reduced
20
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicell
OMCL
|
+$6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$4.76M |
| 3 |
Nektar Therapeutics
NKTR
|
+$4.75M |
| 4 |
SHPG
Shire pic
SHPG
|
+$2.4M |
| 5 |
ENTL
Entellus Medical, Inc. Common Stock
ENTL
|
+$1.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XENT
Intersect ENT, Inc
XENT
|
+$8.92M |
| 2 |
ENZ
Enzo Biochem, Inc.
ENZ
|
+$6.7M |
| 3 |
HealthStream
HSTM
|
+$3.4M |
| 4 |
LHCG
LHC Group LLC
LHCG
|
+$2.04M |
| 5 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$1.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.62% |
| 2 | Miscellaneous | 2.4% |
| 3 | Energy | 2.09% |
| 4 | Communication Services | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRX
1
DELISTED
Akorn Inc
AKRX
| $24.6M | 8.24% |
732,462
-43,129
| -6% | -$1.4M |
|
2
NeoGenomics
NEO
$2.45B
| $24M | 8.05% |
2,679,271
+25,617
| +1% | +$203K |
|
3
AtriCure
ATRC
$2.86B
| $23.3M | 7.8% |
958,858
+2,400
| +0.3% | +$51K |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $18.1M | 6.07% |
2,048,643
-47,852
| -2% | -$336K |
|
|
5
Omnicell
OMCL
$1.49B
| $12M | 4.02% |
278,294
+144,471
| +108% | +$6M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $11.5M | 3.85% |
69,519
+13,728
| +25% | +$2.4M |
|
|
7
Nektar Therapeutics
NKTR
$2.25B
| $9.19M | 3.08% |
31,346
+16,451
| +110% | +$4.75M |
|
8
Harvard Bioscience
HBIO
$36.6M
| $9.11M | 3.06% |
357,220
+36,771
| +11% | +$910K |
|
|
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $8.82M | 2.96% |
524,509
-97,729
| -16% | -$1.46M |
|
|
TLGT
10
DELISTED
Teligent, Inc
TLGT
| $8.68M | 2.91% |
94,846
-92
| -0.1% | -$7.83K |
|
|
ENTL
11
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $8.49M | 2.85% |
512,416
+104,919
| +26% | +$1.46M |
|
|
SPNC
12
DELISTED
Spectranetics Corp
SPNC
| $8.36M | 2.8% |
217,637
+35,481
| +19% | +$1.02M |
|
|
XENT
13
DELISTED
Intersect ENT, Inc
XENT
| $7.65M | 2.57% |
273,645
-393,859
| -59% | -$8.92M |
|
14
Ligand Pharmaceuticals
LGND
$5.44B
| $7.6M | 2.55% |
100,385
-27
| -0% | -$1.89K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $7.39M | 2.48% |
92,761
-704
| -0.8% | -$50.9K |
|
|
KTWO
16
DELISTED
K2M Group Holdings, Inc
KTWO
| $6.61M | 2.22% |
271,495
-203
| -0.1% | -$4.51K |
|
17
Veracyte
VCYT
$3.2B
| $6.29M | 2.11% |
754,560
+33,682
| +5% | +$275K |
|
|
LHCG
18
DELISTED
LHC Group LLC
LHCG
| $6.24M | 2.09% |
91,917
-34,206
| -27% | -$2.04M |
|
|
AMED
19
DELISTED
Amedisys
AMED
| $5.81M | 1.95% |
92,535
-14
| -0% | -$815 |
|
|
MODN
20
DELISTED
MODEL N, INC.
MODN
| $5.63M | 1.89% |
423,211
+2,461
| +0.6% | +$29.4K |
|
21
Halozyme
HALO
$12.1B
| $5.34M | 1.79% |
416,579
+1,968
| +0.5% | +$26.3K |
|
|
MDCO
22
DELISTED
Medicines Co
MDCO
| $5.27M | 1.77% |
138,543
+1,804
| +1% | +$80.3K |
|
23
Heron Therapeutics
HRTX
$59.3M
| $5.09M | 1.71% |
367,390
+3,701
| +1% | +$53.6K |
|
|
24
HealthStream
HSTM
$865M
| $4.9M | 1.64% |
186,044
-123,887
| -40% | -$3.4M |
|
|
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
| $4.79M | 1.61% |
571,629
+5,297
| +0.9% | +$43.3K |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, First Light Asset Management held 56 positions worth $298M, up 14% from $262M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
First Light Asset Management's Q2 2017 filing shows 4 new, 19 increased, 20 reduced and 1 closed positions. Its largest new stake was NEVRO CORP.: 59,358 shares worth $4.42M. The largest sale was Intersect ENT, Inc, an estimated $8.92M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Energy.
- First Light Asset Management's largest Q2 2017 buy was NEVRO CORP.: 59,358 shares worth $4.42M.
- First Light Asset Management added most to Omnicell in Q2 2017, an estimated $6M increase.
- First Light Asset Management's biggest Q2 2017 reduction was Intersect ENT, Inc, cutting an estimated $8.92M.
- First Light Asset Management fully exited Chembio diagnostics, Inc. in Q2 2017, selling an estimated $294K.
- First Light Asset Management's ten largest holdings make up 50% of its $298M portfolio in Q2 2017.
- First Light Asset Management opened 4 new positions and closed 1 in Q2 2017.
- First Light Asset Management's portfolio value rose 14% quarter-over-quarter to $298M.
Based on First Light Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.